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Gene expressionInterferon regulatory factors (IRFs) are critical mediators of gene expression, cell growth and immune
responses. We previously demonstrated that interferon (IFN) induction of early viral transcription and
replication in several mucosal HPVs requires IRF-1 binding to a conserved interferon response element (IRE).
Here we show that the IRF-2 protein serves as a baseline transactivator of the HPV-16 major early promoter,
P97. Cotransfections in IRF knockout cells conﬁrmed that basal HPV-16 promoter activity was supported by
both IRF-1 and IRF-2 complexes interacting with the promoter-proximal IRE in a dose-dependent manner.
Furthermore, HPV-16 E7 expression downregulates the IRF-2 promoter, thus linking IRF-2 levels to viral
transforming gene expression through a negative feedback mechanism. Taken together, these observations
reveal a complex viral strategy utilizing multiple signal transduction pathways during the establishment and
maintenance of HPV persistence.ter, Iowa City, IA 52242, USA.
.
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The family of interferon regulatory factors (IRFs) positively and
negativelymodulates viral and cellular gene expression in response to
a variety of extracellular signals (Fujita et al., 1989; Honda and
Taniguchi, 2006) and are critical mediators of cell immunity and
oncogenesis (Tamura et al., 2008). Interferon regulatory factor (IRF)-1
has been shown to be important for the regulation of cell growth
(Romeo et al., 2002; Tanaka et al., 1994; Taniguchi et al., 2001), a
potent modulator of HPV early gene expression and replication in
keratinocytes (Herdman et al., 2006; Lace et al., 2009a). IRF-1 has also
been shown to be an important modulator of IFN-dependent
attenuation of telomerase activity (Lee et al., 2003) and a critical
component of the enhanceosome assembly within the histone H4
promoter (Kim and Maniatis, 1997).
IRF-2 was originally described as a repressor of IRF-1-mediated
activation through direct competition for binding to conserved IRF
binding elements found in numerous promoters (Harada et al., 1989;
Tanaka et al., 1993; Yamamoto et al., 1994). However, IRF-2 has also
emerged as a complex and distinct mediator of gene expression and
cell cycle control (Pettersson et al., 2009; Vaughan et al., 1998). In
addition to a C-terminal repressor domain that may contribute topost-induction repression of IRF-1 dependent, IFN-mediated activa-
tion, the IRF-2 oncoprotein was also shown to harbor an activation
domain (Yamamoto et al., 1994).
Similar to other viruses, HPVs have evolved strategies to
counteract interferon signaling. We have previously demonstrated
that low levels of interferons stimulate viral early gene transcription
and genome replication through activation of IRF-1 binding to a
conserved interferon response element (IRE) in the major early HPV
gene promoters. We further observed that the conserved IRE also
binds IRF-2 in mobility shift assays in vitro and with chromatin-bound
HPV-16 plasmids in transfected keratinocytes (Lace et al., 2009a).
Both the IRF-1 and IRF-2 promoters appear to be coordinately
modulated by a complex regulatory network in which Stat factors
activate the IRF-1 promoter while IRF factors activate expression of
IRF-2 through conserved promoter response elements (Harada et al.,
1994; Wang et al., 2008).
The HPV transforming proteins interact with multiple cellular
targets (Hebner and Laimins, 2006; McLaughlin-Drubin and Munger,
2009; Sdek et al., 2006; Zhang et al., 2006), including cytokine-
responsive IRF family members (Chang and Laimins, 2000; Koromilas
et al., 2001; Woodworth, 2002). The HPV E6 oncoprotein has been
shown to inhibit IRF-3 activity (Ronco et al., 1998) while the E7 gene
product has been shown to inhibit both the IRF-1 (Cordano et al.,
2008; Perea et al., 2000; Um et al., 2002) and IRF-9 (or “p48”)
(Antonsson et al., 2006). In this study, we demonstrate for the ﬁrst
time that basal levels of IRF-2 can stimulate HPV-16 early gene
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is dependent on IRF-2 binding to the HPV-16 IRE in vitro. Furthermore,
we found that expression of the HPV-16 E7 can downregulate the IRF-
2 promoter in vivo as part of a negative feedback mechanism. These
results further illustrate that mucosal HPVs, such as HPV-16, have
developed complex strategies to subvert multiple IRF- dependent
cellular pathways and integrate viral gene expression with cellular
responses to a variety of extracellular cues in the course of HPV
infection and persistence.
Results
Both IRF-2 and IRF-1 activate the HPV-16 P97 promoter in vivo
Control elements immediately upstream of the HPV-16 major
early promoter (P97) modulate the expression of the E6 and E7
transforming genes (Fig. 1A). In the absence of the viral E2 gene
products, cellular factors have been shown to activate the major early
promoter of HPV-16 (Cripe et al., 1987, 1990; Ishiji et al., 1992) and
other papillomaviruses during the establishment phase of the viral life
cycle (Haugen et al., 2009). While the viral E2 protein represses HPV-
16 P97 activity from the promoter-proximal position, cell factors
competitively binding to overlapping motifs serve as transactivators.
In addition to previously reported IRF-1 binding to the early promoter
of HPV-16 (Arany et al., 2003), we had also described conserved IFN-
responsive IREs in the major early promoters of several mucosal HPVs
capable of binding both IRF-1 and IRF-2 (Lace et al., 2009a).
In this study, we found that the HPV-16 IRE and its ﬂanking
sequences (nt 33–65) (Fig. 1A, clone b) was capable of activating
transcription initiation of a minimal heterologous tk promoter over
13-fold in G-free in vitro transcription assays (Fig. 1A, lane 2) in the
absence of IFN treatment and HPV-16 E2 expression in HeLa cells. This
critical cis region also stimulated the activity of a minimal promoter in
cooperation with a heterologous SV40 enhancer in CAT reporter
assays (Fig. 1B, construct c) while a construct containing consensus E2
motifs was unresponsive in parallel (Fig. 1B, construct a). These
results demonstrate that factors bound to the HPV-16 promoter-
proximal IRE can cooperate with cellular transacting factors bound to
upstream cis elements to activate a minimal promoter. To further
delineate the contribution of the HPV-16 IRE to this basal promoter
function, we synthesized reporter constructs containing multiple
copies of the minimal (16) IRE wt (nt 47–58, 5′-TGAACCGAAACC-3′)
and IRE mutant sequence. These constructs were transfected in a
spontaneously immortalized keratinocyte cell line (HaCaT) and
primary human foreskin keratinocytes (Fig. 1B) as models of the
natural host cells for HPV infection. The (16) IRE (x6) wt exhibited
robust promoter activities (6–10 fold over baseline) in contrast to the
(16) IRE (x6) mut (Fig. 1B, compare clone e and f). These results
demonstrate that the (16) IRE alone is sufﬁcient to drive the
comparable activity of both a heterologous minimal promoter and
the native major early promoter of HPV-16 in keratinocytes.
The 1 kb HPV-16 P97-cat promoter constructs harboring the
conserved IRE - nt 47–58 (5′-TGAACCGAAACC-3′) and additional IRF
promoter reporters (as shown in Fig. 1C) were cotransfected with
increasing amounts of IRF-1 and IRF-2 expression plasmids in human
keratinocyte (HaCaT) cells. We observed dose-dependent activation
of the IRF-dependent HPV-16 wt and IRF-2-cat constructs but not the
IRF-independent IRF-1-cat or the HPV-16 IRE mut reporter constructs
upon addition of IRF-1 or IRF-2 expression plasmids (Fig. 1D). The
HPV-16 IREmut carries a mutation previously shown to abrogate IRF-
1 binding and IFN- mediated activation of the P97 promoter (Lace et
al., 2009a). We observed similar dose-dependent activation of the
same IRF-responsive reporters in transient cotransfections of an
embryonal carcinoma cell line, P19 (data not shown), which harbors
low endogenous levels of both IRF-1 and IRF-2 (Figs. 3 and 4). The
HPV-16 IRE(x6) wt was also stimulated by cotransfection of IRF-1 orIRF-2. In contrast, multiple tandem copies of a cellular IRF-responsive
element (“55-C1B-cat”) were activated by increasing IRF-1 but not
IRF-2, indicating that IRF-2 may require interaction with additional
cell factors to achieve optimal promoter activation (Fig. 1D).
We also compared the baseline activities of the HPV-16 wt and IRE
mut constructs in knockout ﬁbroblast cell lines in which IRF-1, IRF-2 or
both IRFs are ablated (Fig. 2). Mutations abrogating IRF binding to the
HPV-16 IRE resulted in a signiﬁcant decrease in promoter activity (Fig. 2A,
left panel). Expression of IRF-1 or IRF-2 in cotransfections activated the
HPV-16wt IRE construct and the IRF-2 promoter but had no effect on the
HPV-16 IREmut and IRF-1 promoter (Fig. 2A, right panel). Loss of either
the IRF-1 or IRF-2 genes in the corresponding (IRF-1−/− or IRF-2−/−)
knockout cells resulted in the same pattern (Fig. 2B and C, respectively),
indicating that disruption of either the IRF-1 or IRF-2 pathway did not
abolish the IRE-dependent HPV-16 promoter response to basal IRF levels
or ectopically expressed IRF-1 or IRF-2. However, simultaneous abroga-
tion of both IRF pathways in the IRF-1/2−/− double knockout cells
resulted in a loss of IRE-dependent baseline activity (Fig. 2D, left panel).
Cotransfection of either IRF expression plasmid restored P97 promoter
activity in these cells, conﬁrming that both IRF-1 and IRF-2 support the
activity of the HPV-16 P97 promoter (Fig. 2D, right panel). Thus, as in
other cell types expressing IRF-1 and IRF-2, the basal activity of the HPV-
16 P97 promoter was dependent on an intact IRE capable of interacting
with endogenous levels of both IRF-1 and IRF-2 in the absence of IFN-
dependent induction.
The ratio of DNA-bound IRF-1 to IRF-2 in uninfected human
keratinocytes is distinct from other cell types
We examined the binding of cellular factors to oligonucleotides
spanning the HPV-16 IRE (Fig. 3B) and a deﬁned cellular control motif,
the ISRE (Fig. 3A), in mobility shift assays as a sensitive comparison of
DNA-binding competent levels of IRF-1 and IRF-2 (as opposed to
measuring total protein levels which reﬂect a composite of both
modiﬁed and unmodiﬁed pools of the IRF gene products) and to
identify potential additional factors contributing to the IRE-depen-
dent P97 promoter activity. Since many of the IRF-responsive cis
elements in viral and cellular promoters are complex composite
regulatory elements, responding to multiple extracellular signals
through distinct intracellular pathways, we also looked for the
binding of alternate cell factor complexes to the HPV-16 IRE in
extracts from various cell types. We noted that in extracts derived
from keratinocytes, the only factors binding to the IRE were IRF-1 and
IRF-2 (Fig. 3B, lanes 1–21). We have conﬁrmed the binding of
papillomavirus regulatory factor (PRF), previously described by
Boeckle et al. (2002), to a motif immediately downstream and
partially overlapping the HPV-16 IRE in vitro (Fig. 3B, lane 1). We also
detected PRF binding activity (though not necessarily concordant
with IRF binding) to conserved motifs in several HPV promoters (data
not shown). However, a complete understanding of the role of this
factor in the modulation of early HPV gene expression remains
elusive. Therefore, consistent with previous competitive footprinting
results with HPV-16 (data not shown), IRF-1, IRF-2 and PRF (which
share similar dissociation constants in vitro) may serve as potential
displacement targets of HPV E2- mediated repression of the P97
promoter (Lace et al., 2009a). Furthermore, we scanned the entire
1 kb HPV-16 P97 promoter region to determine whether or not
additional IFN-related complexes bound to additional IFN-responsive
HPV-16 cis elements. Surprisingly, we found no evidence of ISGF-3 or
Stat-1 dimer binding to an overlapping set of oligonucleotides
spanning nucleotides (7000 to +153) of the 1 kb P97 promoter in
vitro (data not shown).
Interestingly, we found that the ratio of DNA-bound IRF-1 to IRF-2
was atypically higher in uninfected keratinocytes (primary foreskin
keratinocytes and a spontaneously immortalized keratinocyte line,
HaCaT) (Fig. 3B, lanes 1–3, 8–10) than in other cell types. Consistent
272 M.J. Lace et al. / Virology 399 (2010) 270–279
273M.J. Lace et al. / Virology 399 (2010) 270–279with previous reports, extracts from human ﬁbroblast (GM-3) and
lymphoid (CA46) cell lines showed signiﬁcantly more IRF-2 binding
compared to limiting levels of IRF-1 (Fig. 3B, lanes 22–24 and 44–46,
respectively). Extracts derived from P19 cells (an embryonal
carcinoma cell line) were included as a “negative” control as these
cells (in contrast to other cell types) harbor low endogenous levels of
both IRF factors (Fig. 3A, lanes 27–30, and Fig. 3B, lanes 37–40).
Interestingly, we noted a similarly high IRF-2 to IRF-1 ratio in the HPV-
positive keratinocyte cell line, HPK1a (Fig. 3B, lanes 15–17), as well as
in HeLa (HPV-18+) and SiHa (HPV-16+) cell extracts (data not
shown). Antisera speciﬁc for IRF family members only found in
lymphoid cells were used with the lymphoid CA46 extract to verify
the presence of these factors and the ability of alternate IRF family
members to bind the HPV-16 IRE (Fig. 3B). Binding of the lymphoid-
speciﬁc IRF family members, ICSAT or ICSBP, or ubiquitous IRF-1 and
IRF-2 to the HPV-16 IRE resulted in complexes withmobilities distinct
from those observed with the control ISRE—a composite IFN-
responsive element from the cellular ISG15 promoter that binds
both a tripartite Stat complex (ISFG-3) and IRF factors to an
overlapping IRE (Fig. 3A, lanes 32–38 and Fig. 3B, lanes 44–50).
These results indicate that while the (16) IRE may exhibit differential
cell factor binding patterns in lymphoid cells, it shares functional
homology with other IFN response elements (such as the ISRE) in
keratinocytes—the natural host cell for HPV infection.
To determinewhether or not the increase in IRF-1 bindingwas due
to differential expression of the IRF-2 and IRF-1 gene products, we
extracted total RNA from a variety of cell lines and compared the
relative expression of IRF-1 and IRF-2 mRNA in RNase protection
assays (Fig. 4). IRF-1 mRNA levels are notably higher than IRF-2 in the
HaCaT cell line and some of the other cell lines tested but not in
primary human keratinocytes (Fig. 4A), leading us to conclude that
increased levels of IRF-1 binding observed in uninfected keratino-
cytes, compared to other cell types, were not solely due to increased
steady state IRF-1 mRNA levels. Similarly, IRF-2 mRNA levels varied
widely between different cell types (Fig. 4B), demonstrating that the
observed variation in IRF-1:IRF-2 binding did not directly correlate
with IRF-1 of IRF-2 steady state mRNA levels.
IRF-2 cooperates with transcriptional activators to modulate promoter
activity
Since members of the IRF family have been shown to cooperate
with other cellular factors and that the HPV-16 IRE functions as a
promoter-proximal activating cis element in cooperation with
transacting factors interacting with upstream enhancer elements
(Fig. 1B), we examined the ability of a chimeric LEX-IRF-2 expression
plasmid to cooperate with other chimeric cellular and viral factors to
activate a minimal promoter construct in vivo (Fig. 5A). We tested the
ability of the IRF-2 effector domain to cooperatively activate a
minimal target containing GAL4 and LEXA binding sites cloned
immediately upstream of a truncated tk-38 promoter in CAT assays.
A variety of cellular and viral transacting domains (TADs) shown to
modulate transcription by various mechanisms (Tasset et al., 1990)
were linked to the GAL4 DNA-binding domain (DBD) and included in
IRF cotransfections. Some of these factors have been previously shown
to speciﬁcally bind to, andmodulate, the native P97 promoter (Lace et
al., 2009a,d; Ushikai et al., 1994). HPV-16 E2 and Sp1 bind to sites that
overlap and extend immediately upstream of the IRF-1/IRF-2 bindingFig. 1. IRF-2 activates the HPV-16 P97 promoter in vivo. (A) Schematic of the HPV-16 genom
IRE) and G-free reporter constructs tested in in vitro transcription assays. The G-free 250 plas
Reporter plasmids with minimal promoters linked to HPV-16 cis elements or consensus fac
assays. “SV2”=SV40 enhancer. Reporters containing wt or mutant multimeric copies of the
HaCaT and primary human foreskin keratinocytes (HFK) and their baseline activities compare
in this study. The previously determined IRF-1-dependent responsiveness of each reporter
HPV-16 P97 wt and IRE mut CAT reporters and increasing amounts of IRF-1 and IRF-2 expr
relative to the baselines, of the P97-cat reporters were compared to that of the IRF-2-cat and Isite of the P97 promoter; however, we observed no cooperative
activation between IRF-2 and Sp1 or E2 chimeric constructs, including
those encoding the full length BPV-1 E2 gene product or discrete
functional E2 domains (MJ Lace et al., unpublished data). We noted
cooperative activation of the minimal promoter when the LEX-IRF-2
was combined with equimolar amounts of vectors expressing the
complete GAL4 protein, GAL4-ATF-1 or the GAL4-TEF-1 (Δ 55–121).
However, no cooperative activation was noted with vectors expres-
sing the AP-2α protein (data not shown).
Since we had demonstrated that Sp1 and the E2 proteins interact
in an orientation-speciﬁc manner to quench the P97 promoter, we
also used the same chimeric constructs to determine if the
cooperative interaction of these factors was similarly orientation-
dependent by using a minimal promoter target with the LEX sites
distal, and GAL4 sites proximal, to the tk start site (Fig. 5B). However,
no steric inhibition of cooperative activation was observed between
the chimeric IRF-2 and these acidic activators in either binding site
orientation in our assays. Taken together, these experiments revealed
that IRF-2 was capable of cooperating with cellular transactivator
domains, including GAL4, ATF-1 and TEF-1—a factor which contri-
butes a critical role in keratinocyte-dependent, major early promoter
activity in HPV-16 (Ishiji et al., 1992).
HPV-16 E7 expression modulates IRF-2 activity in vivo
The HPV-16 E7 gene product has previously been shown to
interact with, and inhibit the function of, the IRF-1 protein (Perea et
al., 2000). Since the IRF-2 promoter (pIRF-2) is responsive to IRF-1
dependent activation, we examined the effect of (16) E7 expression
on pIRF-2 activity in vivo (Fig. 6). Increasing amounts of an HPV-16 E7
expression plasmid downregulated the IRF-2 promoter but had no
effect on other promoters in parallel. Expression of the HPV-16 E6 and
adenovirus E1a transactivator (Lillie and Green, 1989; Liu and Green,
1994) had little effect on IRF-2 promoter activity in parallel in an HPV-
negative, cervical carcinoma cell line (C33A). These results demon-
strate that the HPV-16 E7 inhibits IRF-2 by directly or indirectly target
IRF-1 or other cell factors critical to the baseline activity of the IRF-2
promoter.
Discussion
In this study, we show that the transcription factor IRF-2 acts as a
baseline promoter factor in the major early gene promoter (P97) of
HPV-16. In contrast to initial reports characterizing a “latent”
activation domain in the IRF-2 protein (Yamamoto et al., 1994), our
assays demonstrated that basal IRF-2 levels and dose-dependent
ectopic expression of IRF-2 were sufﬁcient to drive robust activation
of the HPV-16 P97 promoter in vivo. Further, IRF-2 is capable of
cooperating with a wide range of cellular transactivators to stimulate
IRE-dependent promoter activities. IRF-2 activation of the HPV-16 P97
promoter is dependent on a conserved IRE which appears to be a
critical promoter element governing responses to multiple cytokines
and growth factors.
IRF-2 activation of the HPV-16 P97 promoter in vivo
Consistent with our previous study (Lace et al., 2009a), the
promoter-proximal IRE interacts with cellular factors to activate E6–e, illustrating the conserved promoter-proximal cis elements (e.g., the IFN-responsive
mid (clone d) and Ad MLP G-free (clone e) plasmids were incorporated as controls. (B)
tor binding motifs were transfected into HeLa cells (clones a–d) and monitored by CAT
HPV-16 IRE linked to a minimal tk-38-cat promoter (clones e, f) were transfected into
d in CAT assays. (C) Schematic of expression plasmids and CAT reporter constructs used
is indicated as “+” or “−“. (D) HaCaT keratinocytes were transiently transfected with
ession plasmids (shown in grey or black bars, respectively). The normalized activities,
RF-1-cat controls in CAT assays and represent averages of 2-4 independent experiments.
Fig. 2. Both IRF-2 and IRF-1 pathways are necessary for HPV-16 P97 basal promoter activity in vivo. The reporter constructs tested in Fig. 1 were also transiently transfected into
(A) wild-type (wt) 3T3 cells, (B) IRF-1−/−(C) IRF-2−/− knockout, and (D) IRF-1/2−/− double knockout (DKO) ﬁbroblast cell lines. In each panel, the baseline activities of the wt
versus the IRE mut HPV-16 P97-cat reporters are compared on the left while cotransfection of the IRF-1 and IRF-2 expression plasmids (3 μg) with the HPV-16 and control
promoters (1 μg) (as illustrated in Fig. 1C) is displayed on the right. Normalized CAT activities, relative to each promoter construct baseline, represent an average of 3–6
independent experiments.
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Fig. 3. The ratio of DNA-bound IRF-1 to IRF-2 in uninfected keratinocytes is distinct from other cell types. (A) Mobility shift assays were performed with nuclear extracts prepared
from a variety of cell types. Speciﬁc complexes were formed with an ISRE/IRE probe from the ISG15 promoter. To detect IRF proteins in these extracts, antisera speciﬁc for the IRF
family members were used to supershift speciﬁc complexes. (B) The binding of IRF family members to the HPV-16 IRE probe (P5 wt) was also monitored in parallel with the same
reagents. “ns”=non-speciﬁc complex. Reactions containing only the probe and antisera mixtures (without extracts) were included as negative controls.
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demonstrates that IRF-2 is a critical component required for HPV-16
IRE function. We have previously demonstrated that TEF-1 is critical
component of the keratinocyte-dependent enhancer activity of the
HPV-16 P97 promoter (Ishiji et al., 1992); therefore, the ability of IRF-
2 to cooperate with TEF-1 to activate transcription may be signiﬁcant
in the context of HPV-16 E6–E7 expression in keratinocytes. Further,
the ability of IRF-2 to cooperate with multiple cellular transactivators,
such as GAL4, ATF-1 and TEF-1, indicates a broader capability to drive
the activity of complex cellular and viral promoters harboring IREs.
Interestingly, we noted atypically higher levels of DNA-bound IRF-
1 compared to IRF-2 in uninfected keratinocytes compared to other
cell types we examined where DNA-bound IRF-2 was predominant.
IRF-2 has been reported to be associated with (and serves as a marker
of) oncogenic progression in human esophageal carcinomas (Wang et
al., 2007); therefore, increased IRF-2 levels in HPV-immortalized
epithelial and other cell lines observed in this study would be
consistent with this model. Both IRF-1 and IRF-2 proteins utilize post-
translational modiﬁcation (i.e., phosphorylation) to stimulate DNAbinding of extant pools of each factor and basal levels of IFN-inducible
cell factors have been shown to modulate constitutive transcription
(Chatterjee-Kishore et al., 2000). It is therefore likely that increased
levels of IRF-1 binding may be due, in part, to enhanced phosphor-
ylation of latent levels of the IRF-1 protein and/or a concomitant
decrease in IRF-2 binding in the uninfected keratinocyte host. The
eventual increase in HPV early gene expression during the establish-
ment of infection may also temper the levels of DNA-bound IRF-1 as
seen in binding assays with the HPV-positive keratinocyte (HPK-I) cell
extracts since E7 has been shown to inactivate IRF-1 (Park et al., 2000;
Perea et al., 2000).
We had previously shown that the conserved IRE was not
absolutely required for HPV-16 persistence per se as we had
generated clonal HPV-immortalized primary keratinocytes harboring
extrachromosomal HPV-16 IREmut genomes at copy numbers similar
to wt (Lace et al., 2009a). Thus, the interaction of IRF-2 and IRF-1 with
the cognate response element in the HPV-16 major early promoter is
not essential for immortalization or plasmid genome maintenance.
However, the ability of the conservedHPV IRE to utilize both IRF-1 and
Fig. 4. IRF-1 and IRF-2 mRNA levels vary between different cell types. Total RNA was
harvested from several cell types and hybridized with the illustrated probes speciﬁc for
the (A) IRF-1 or (B) IRF-2 messages in RNase protection assays. A probe speciﬁc for the
28Smessage was included as an internal control in each reaction. All lanes were derived
from the same exposure of the respective experiments. Ratios of the IRF-1 and IRF-2
mRNAs associated with each cell type are listed below (B).
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both immunoreactive IRF pathways by utilizing shifting basal and
cytokine-induced levels of either factor throughout the viral life cycle
and is consistent with other viral models of IRF-1/IRF-2-dependentFig. 5. IRF-2 cooperates withmultiple heterologous transcriptional activator domains to
modulate promoter activity. (A) A chimeric LEX-IRF-2 was cotransfected with an array
of chimeric GAL-transacting factor expression plasmids and a GAL4x1-LEXx2 tk-38 cat
reporter in C33A cells. The LEX DBD control was cotransfected with the same array of
GAL4-binding chimeric constructs in parallel as negative controls. (B) Combinations of
chimeric activators that cooperatively activated the minimal promoter target in (A) (as
shown in the boxed areas) were cotransfected with a LEXx6 GAL4x5-tk-38 cat reporter
to detect orientation-dependent cooperativity. Relative CAT activities are normalized to
the GAL4-DBD + LEX-DBD cotransfection baseline (circled) and represent averages of
3–5 independent experiments.transcriptional regulation (Battistini et al., 2002). We have not
detected the binding of any additional IRF family members to the
HPV-16 IRE but cannot rule out that additional complexes may form
Fig. 6. HPV-16 E7 expression downregulates the IRF-2 promoter in vivo. HPV-16-cat,
IRF-1-cat, 55-C1B-cat and IRF-2-cat reporters (as illustrated in Fig. 1C) and the Ad E2-
cat were transiently cotransfected with pCG plasmids expressing the HPV-16 E6, E7 or
adenovirus E1a genes in the HPV-negative, C33A cells. Relative CAT activities are
expressed as fold above or below normalized baseline activity (transfection with pCG-
neo alone) and represent averages of 2–4 independent experiments.
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to immunoreactive signal transduction pathways.
Thus, basal levels of both IRF-2 and IRF-1 would support initial
expression of the HPV gene products immediately after infection.
Cellular immune responses would induce IRF-1-dependent activation
of viral gene expression and genome ampliﬁcation during the
establishment phase of the viral life cycle. During the persistence
phase, shifting basal levels of IRF-2 or IRF-1would continue to support
expression of the viral oncogenes critical for immortalization while
binding of the HPV E2 gene products to an overlapping motif could
potentially inhibit this activity by competitively displacing IRFs bound
the conserved IRE.
The HPV-16 E7 gene product downregulates IRF-2 promoter activity
Certain IRF pathways are attenuated in the course of HPV infection
and tumorigenic progression (Bachmann et al., 2002; Sdek et al.,
2006). In addition to potential HPV E2-dependent displacement of IRF
binding to overlapping motifs, we also found that expression of the
HPV-16 E7 oncoprotein downregulates the IRF-2 promoter in vivo.
This presumably occurs through the direct interaction of the E7
protein with IRF-1 (Park et al., 2000; Perea et al., 2000; Um et al.,
2002). The E7-dependent inactivation of IRF-1 would predictably
impact IRF-2 expression since IRF-1 activates the pIRF-2 promoter by
binding to a deﬁned IRE (Harada et al., 1994). E7 and E1a proteins
share functional roles in cell immortalization as both target the cell
cycle regulator Rb, resulting in the release of the E2F-1 activator
which can in turn stimulate E2F-responsive promoters downstream.
Because the effect of E7 on the IRF-2 promoter also takes place in C33
carcinoma cells in which Rb is inactive (Scheffner et al., 1991; Wrede
et al., 1991), we conclude that E7 downregulates the IRF-2 promoter
by inactivating IRF-1 and/or other cell factors rather than through the
Rb/E2F pathway.
HPV infection is associated with an altered immunogenic proﬁle of
keratinocytes in vivo (Delvenne, 2005; Kobayashi et al., 2008)
including altered cytokine expression (Alazawi et al., 2002; Stanley,
2008). A complex array of signal transduction pathways have been
shown to modulate transcription from viral and cellular genes by
multiple mechanisms (Brivanlou and Darnell, 2002) and a range of
cytokines, growth factors and steroid hormones have been shown to
modulate the activity of HPV promoters (Chan et al., 1989; Peto et al.,
1995; Woodworth, Notario, and DiPaolo, 1990). We noted that the
HPV-16 P97, pIRF-1 and pIRF-2 promoters are stimulated by IL-6, EGF
or TGF-beta1 treatment (data not shown), indicating that multiple
external factors can activate distinct signal transduction pathways
(Leaman et al., 1996; Watanabe and Arai, 1996) to modulate early
HPV gene expression in keratinocytes. These results suggest that
multiple signal transduction pathways converge at the HPV-16 IRE
possibly in the form of alternate induced IRE-binding complexes or via
induction of additional cellular factors bound to other cis control
elements in the complex major early promoter which in turn
cooperate with IRF-2 bound to the IRE to drive early HPV gene
expression. Both mechanisms could also be further inﬂuenced by
cross talk between distinct signaling pathways—a common mecha-
nism in cytokine-mediated transcriptional control. These results are
consistent with a regulatory network that potentially integrates the
effects of basal IRF-1/IRF-2 levels with a wide range of extracellular
cues to stimulate a common promoter element(s) in HPVs.
In summary, we have demonstrated that in the absence of IFN
induction, basal levels of the IRF-2 protein activate HPV-16 E6–E7
expression by binding to a conserved IRE in the major early promoter,
P97. These results also demonstrate that increased E7 expression in
turn downregulates the IRF-2 promoter, revealing a complex negative
feedback mechanism governing HPV early gene expression in
response to critical signal transduction pathways, such as IRF-2,
associatedwith immunosurveillance and the regulation of cell growth.Materials and methods
Cell culture
Primary human foreskin keratinocyte (HFK) cultures were
prepared from neonatal foreskins as described (Rheinwald and
Green, 1975) and were grown on irradiated J2 ﬁbroblast feeder cells
in E media, containing 0.5 μg/ml hydrocortisone, 0.1 nM choleratoxin,
5 μg/ml transferrin, 5 μg/ml insulin, 2 nM 3,3′-5-triodo-L-thyronine
and 5 ng/ml epidermal growth factor (Hubert et al., 1999; Lace et al.,
2009b). The IRF knockout ﬁbroblast cell lines (Tanaka et al., 1994) and
NIH 3T3 cells were cultured in 7% DMEM. HaCaT cells, a spontaneously
immortalized human keratinocyte cell line that retains its capacity for
in vivo differentiation, were a gift from Dr. N. Fusenig (Boukamp et al.,
1988). The HPV-positive keratinocyte (HPK)-I cells, which harbor a
low copy number integrated HPV-16 genome, were a gift from M.
Dürst (Dürst et al., 1995). HPV-negative (C33A), HPV-18-positive
cervical carcinoma cells (HeLa) and CA46 cells (Magrath et al., 1980)
were cultured as described (Ishiji et al., 1992; Ushikai et al., 1994).
P19, an embryonal carcinoma cell line, the IRF knockout ﬁbroblast cell
lines (Tanaka et al., 1994), human ﬁbroblast (GM3) and NIH 3T3 cells
were cultured in 7% DMEM.
Plasmid constructions and transcription assays
The HPV-16 P97-cat plasmids were constructed and tested in
chloramphenicol acetyl transferase (CAT) assays as described (Cripe
et al., 1990). The IRF-2-cat and IRF-1-cat reporter constructs (Harada
et al., 1994) were tested in parallel. The Ad E2-cat and Ad E1a
expression plasmid (Imperiale et al., 1985) were gifts from Dr. Mark
Stinski (University of Iowa). The GAL4 DBD (aa 1–147) and LEX DBD
(aa 1–202) expression plasmids were kind gifts from Dr. M. Green and
Dr. M. Ptashne. The minimal tk-38-cat reporters and chimeric GAL4
and LEXA expression plasmidswere constructed as described (Ushikai
et al., 1994). The pCG (16) E6 and pCG (16) E7 expression plasmids
were gifts from Dr. Lawrence Banks (Trieste, It). PCR-generated
probes were used in RNase protection assays as described (Ishiji et al.,
1992; Lace et al., 2009c; Ushikai et al., 1994). Total RNAwas harvested
from transfected HeLa cells using RNAqueous kits (Ambion, Austin,
TX) for analysis as described (Ushikai et al., 1994). HPV-16 and E2
consensus site (E2x2) G-free plasmids were synthesized via a single
round of PCR and veriﬁed by automated sequencing. The HPV-16 G-
free PCR products extend to nt +111, incorporating G to C
278 M.J. Lace et al. / Virology 399 (2010) 270–279transversions at nt +101 and +106. These nucleotide substitutions
were found to ensure P97 initiated G-free transcripts. The PCR
products were digested with EcoR I and PmL I and linked to a 380
nucleotide G-free cassette, G-free 380 (a gift from R. Cortese). The Ad
MLP G-free110 plasmid was a gift from R. Roeder. G-free in vitro
transcription assays were performed as previously described (Lace et
al., 2009d).
Protein puriﬁcation and mobility shift assays
Binding was performed in 25 μl at 0.1–0.3 nM (15,000 cpm) of
32P end-labeled gel-puriﬁed oligonucleotides, 10 or 30 nM of
unlabeled poly (dI-dC)(dI-dC) (Amersham-Pharmacia, Piscataway,
NJ) and BPV E2#10 as nonspeciﬁc competitors and unlabeled speciﬁc
competitor oligonucleotides at indicated concentrations. Protein–
DNA complexes and unbound probe were resolved on nondenaturing
6% polyacrylamide gels and visualized by autoradiography. Dissoci-
ation constants (KD) were determined by densitometric scanning
from three or more competition experiments as described (Ushikai et
al., 1994). Nuclear extracts were prepared from primary human
keratinocytes (HFK), primary human ﬁbroblasts (GM3), HaCaT, a
squamous cell carcinoma cell line (SCC13), P19, an HPV-16-integrated
keratinocyte line (HPK-I), and a lymphoid cell line, CA46. All
competent extracts were prepared by the ammonium sulfate protocol
as described (Cripe et al., 1990; Ishiji et al., 1992) and pretested by
monitoring comparable binding of cell factors, such as AP-1 and/or
TEF-1. In vitro translations of recombinant IRF-1 and IRF-2 were
performed in a coupled transcription/translation system (TNT kit,
Promega, Madison, WI) using IRF-1, -2 expression plasmids, pCMIRS
(Fujita et al., 1989) and pIRF2-5 (Harada et al., 1989), respectively,
and puriﬁed as described (Lace et al., 2009a). The supershifting of
EMSA complexes with polyclonal Stat or IRF antisera (Santa Cruz
Biotechnology, Inc., Santa Cruz, CA) followed manufacturer protocols.
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